Press Releases

 
Press Releases
  Date Title and Summary View
Jan 16, 2007
WOBURN, Mass.--(BUSINESS WIRE)--Jan. 16, 2007--ArQule, Inc. (NASDAQ: ARQL) today provided an update on its clinical trials with three compounds: ARQ 197, a proprietary, orally administered small molecule inhibitor of the c-Met receptor tyrosine kinase; ARQ 501, a first-generation Activated Checkpoint Therapy(SM) (ACT) candidate; and ARQ 171...
Jan 17, 2007
WOBURN, Mass.--(BUSINESS WIRE)--Jan. 17, 2007--ArQule, Inc. (Nasdaq: ARQL) today announced that Michael D. Loberg, Ph.D., has been named to its board of directors. Dr. Loberg brings 27 years of senior management and drug development experience to ArQule, including leadership positions at NitroMed, Inc. and Bristol Myers Squibb Company. ...
Jan 29, 2007
WOBURN, Mass.--(BUSINESS WIRE)--Jan. 29, 2007--ArQule, Inc. (NASDAQ: ARQL) and the chairman of its scientific advisory board, Dr. Chiang J. Li, today announced a $5.0 million sponsored research agreement with the newly established Boston Biomedical, Inc. (BBI), an independent corporation. ArQule and Dr. Li have agreed that he will transitio...
Feb 1, 2007
WOBURN, Mass.--(BUSINESS WIRE)--Feb. 1, 2007--ArQule, Inc. (Nasdaq: ARQL) today announced that it will report its financial results for Fiscal 2006 year-end and fourth quarter on Thursday, February 8, 2007 at 7:00 a.m. (eastern time), and hold a conference call at 9:00 a.m. (eastern time). Dr. Stephen A. Hill, ArQule's president and chief e...
Feb 8, 2007
WOBURN, Mass.--(BUSINESS WIRE)--Feb. 8, 2007--ArQule, Inc. (NASDAQ: ARQL) today announced that it will present at the BioCEO & Investor Conference on Wednesday, February 14, 2007 at 1:30 p.m. eastern time. ArQule's presentation will be webcast live and can be accessed through the investor relations section of the Company's website. The ...
Feb 8, 2007
WOBURN, Mass.--(BUSINESS WIRE)--Feb. 8, 2007--ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the year and for the fourth quarter ended December 31, 2006. The Company reported a net loss of $31,440,000 or $0.88 per share, for the year ended December 31, 2006, compared with a net loss of $7,520,000, or $0.22 ...
Mar 14, 2007
WOBURN, Mass.--(BUSINESS WIRE)--March 14, 2007--ArQule, Inc. (NASDAQ: ARQL) today announced that the American Society of Clinical Oncology (ASCO) has accepted for oral presentation the Company's abstract for ARQ 197 (A Phase 1 Dose Escalation Study of ARQ 197, a Selective Inhibitor of the c-Met Receptor in Patients with Metastatic Solid Tum...
Apr 4, 2007
WOBURN, Mass.--(BUSINESS WIRE)--April 4, 2007--ArQule, Inc. (NASDAQ: ARQL) today announced that it will present at the CIBC Annual Biotechnology & Specialty Pharmaceuticals Conference on Wednesday, April 11, 2007 at 12:45 p.m. eastern time. ArQule's presentation will be webcast live and can be accessed through the investor relations sec...
Apr 18, 2007
WOBURN, Mass.--(BUSINESS WIRE)--April 18, 2007--ArQule, Inc. (NASDAQ: ARQL) today announced that eleven abstracts submitted by the Company were presented at the 2007 Annual Meeting of the American Association for Cancer Research (AACR), April 14-18, 2007 in Los Angeles. The AACR abstracts are based on pre-clinical studies that provide a rat...
Apr 19, 2007
WOBURN, Mass.--(BUSINESS WIRE)--April 19, 2007--ArQule, Inc. (NASDAQ: ARQL) today announced that it will present at the 7th Annual Fortis Biotechnology Conference on Wednesday, April 25, 2007 at 9:15 a.m. eastern time (14:15 p.m. UK). ArQule's presentation will be webcast live and can be accessed through the investor relations section of th...
Page:
1
... NextLast
= add release to Briefcase

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300